Roche’s Perjeta shows significant promise in phase 3 breast cancer trial

Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This drug cocktail has been shown to significantly reduce the risk of disease recurrence and extend the lifespan of patients with an aggressive form of early breast cancer.

Groundbreaking Results in Breast Cancer Treatment

The trial, which compared the efficacy of Perjeta combined with Herceptin and chemotherapy against Herceptin and chemotherapy alone as adjuvant therapy following cancer surgery, met its primary endpoint. Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development, expressed optimism about the findings: “These results from the positive APHINITY study represent an important addition to the body of data for Perjeta in the treatment of people with HER2-positive early breast cancer.”

The study involved 4,805 patients with operable HER2-positive early breast cancer (eBC) and demonstrated that the combination therapy significantly reduced the risk of both the recurrence of breast cancer as well as death compared to the control group.

Enhancing Patient Outcomes Through Advanced Therapy

Perjeta acts by targeting the HER2 receptor, which is present in excessive quantities on the surface of cancer cells in HER2-positive patients. It prevents the HER2 receptor from pairing with other HER receptors on the cell surface, which is believed to inhibit tumor growth and survival.

This mechanism of action has proven effective in the neoadjuvant setting (prior to surgery) and is now showing significant benefits in the adjuvant setting (post-surgery), indicating a comprehensive treatment approach for patients with this type of breast cancer.

Regulatory Path Forward and Clinical Implications

Following these positive results, Roche looks forward to discussing these adjuvant results with global regulatory authorities. The therapy is already approved in over 75 countries as a neoadjuvant treatment for HER2-positive eBC, and approval as an adjuvant treatment could make it a complete treatment regimen for this patient population.

Gunther von Minckwitz, MD, study coordinator from the Breast International Group, highlighted the importance of such studies: “APHINITY provides yet another example of the importance of industry-academic collaborations and their value in advancing cancer care for people affected by this challenging disease.”

The success of the APHINITY trial is a significant advancement in the fight against breast cancer. By effectively reducing the recurrence of the disease and extending patients’ lives, Perjeta, in combination with Herceptin and chemotherapy, may set a new standard of care for treating early-stage HER2-positive breast cancer. It exemplifies the potential of targeted therapies to improve clinical outcomes in oncology, particularly for aggressive cancer forms.